Literature DB >> 10989266

Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.

M E Liechti1, M R Saur, A Gamma, D Hell, F X Vollenweider.   

Abstract

MDMA (3,4-methylenedioxymethamphetamine, "Ecstasy") mainly releases serotonin and dopamine. In animals, pretreatment with 5-HT(2) antagonists has been shown to attenuate neurochemical and behavioral effects of MDMA. In humans, the role of 5-HT(2) receptors in the action of MDMA has not been studied. We investigated the effect of pretreatment with the 5-HT(2A/C) antagonist ketanserin (50 mg p.o.) on subjective responses to MDMA (1.5 mg/kg p.o.) in 14 healthy volunteers using a double-blind placebo-controlled within-subject design. Subjective effects were rated by psychometric rating scales. Physiological effects measured were blood pressure, heart rate, and body temperature. Adverse effects were assessed during the sessions, and after one and three days. Ketanserin attenuated MDMA-induced perceptual changes, emotional excitation, and acute adverse responses but had little effect on MDMA-induced positive mood, well-being, extroversion, and short-term sequelae. Body temperature was lower under MDMA plus ketanserin compared to MDMA alone. The results suggest a contributing role for 5-HT(2) receptors in the action of MDMA in humans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10989266     DOI: 10.1016/S0893-133X(00)00126-3

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  62 in total

1.  Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans.

Authors:  Cm Hysek; Y Schmid; A Rickli; L D Simmler; M Donzelli; E Grouzmann; M E Liechti
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 2.  The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals.

Authors:  Philip Kamilar-Britt; Gillinder Bedi
Journal:  Neurosci Biobehav Rev       Date:  2015-09-25       Impact factor: 8.989

3.  Environment Influencing Serotonin Syndrome Induced by Ecstasy Abuse.

Authors:  Rui Tao; Ibrahim M Shokry; John J Callanan
Journal:  Ann Forensic Res Anal       Date:  2017-03-07

4.  Successful treatment of intractable visual hallucinations with 5-HT 2A antagonist ketanserin.

Authors:  Iris E C Sommer; Hidde Kleijer; Lucy Visser; Teus van Laar
Journal:  BMJ Case Rep       Date:  2018-06-27

5.  Altered Insula Connectivity under MDMA.

Authors:  Ishan C Walpola; Timothy Nest; Leor Roseman; David Erritzoe; Amanda Feilding; David J Nutt; Robin L Carhart-Harris
Journal:  Neuropsychopharmacology       Date:  2017-02-14       Impact factor: 7.853

6.  Initial deficit and recovery of function after MDMA preexposure in rats.

Authors:  K A Brennan; S Schenk
Journal:  Psychopharmacology (Berl)       Date:  2005-12-16       Impact factor: 4.530

7.  Pharmacological profile of novel psychoactive benzofurans.

Authors:  Anna Rickli; Simone Kopf; Marius C Hoener; Matthias E Liechti
Journal:  Br J Pharmacol       Date:  2015-04-24       Impact factor: 8.739

8.  Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits.

Authors:  N P Pedersen; W W Blessing
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

9.  Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.

Authors:  Onica Legendre; Stevan Pecic; Sandeep Chaudhary; Sarah M Zimmerman; William E Fantegrossi; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2009-11-20       Impact factor: 2.823

10.  Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.

Authors:  M Farré; R de la Torre; B O Mathúna; P N Roset; A M Peiró; M Torrens; J Ortuño; M Pujadas; J Camí
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.